Advanced in Prothrombin Deficiency

Dr. Naveed M. Chowhan

Jackson County Schneck Memorial Hospital
Seymour, IN
Advanced
in Prothrombin Deficiency
Specialties:Hematology Oncology | Oncology
Accepting New Patients
43 Years of Experience
OverviewInsuranceLocationsClinical Research

Overview

Naveed Chowhan is a Hematologist Oncology specialist and an Oncologist in Seymour, Indiana. Dr. Chowhan has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Hemangioma Thrombocytopenia Syndrome, Thrombocytopenia, Congenital Antithrombin 3 Deficiency, Hereditary Resistance to Anti-Vitamin K, and Bone Marrow Aspiration. Dr. Chowhan is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1982
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in IN
Hospital Affiliations
Schneck Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Anthem
  •  CareSource
  •  Humana

Locations

JACKSON COUNTY SCHNECK MEMORIAL HOSPITAL
411 W Tipton St, Schneck Medical Center, Seymour, IN 47274
812-522-2349

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2024
Intervention Type: Drug, Other
Study Drug: Ribociclib
Study Phase: Phase 3
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2024
Intervention Type: Drug
Study Drugs: Lasofoxifene, Fulvestrant
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: December 09, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Topical Cream (UTC) in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
A Phase 1-2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of 0.1% Uracil Topical Cream (UTC) in the Prevention of Hand-Foot Syndrome (HFS) in Patients With Metastatic Breast Cancer Treated With Capecitabine
Enrollment Status: Completed
Publish Date: October 08, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

2 Total Publications

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: May 18, 2020
Similar Doctors
Expertise in
30
conditions
Dr. Rakesh P. Mehta
Hematology | Hematology Oncology | Oncology
Expertise in
30
conditions
Dr. Rakesh P. Mehta
Hematology | Hematology Oncology | Oncology

University Medical Diagnostic Associates Inc

550 N University Blvd, 
Indianapolis, IN 
 (58.7 mi)
217-274-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Rakesh Mehta is a Hematologist and a Hematologist Oncology provider in Indianapolis, Indiana. Dr. Mehta and is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Sickle Cell Disease, Thrombocytopenia, Hemoglobin SC Disease, and Chronic Lymphocytic Leukemia (CLL). Dr. Mehta is currently accepting new patients.

Expertise in
40
conditions
Dr. Naveen Manchanda
Hematology | Hematology Oncology | Oncology
Expertise in
40
conditions
Dr. Naveen Manchanda
Hematology | Hematology Oncology | Oncology

University Medical Diagnostic Associates Inc

550 N University Blvd, 
Indianapolis, IN 
 (58.7 mi)
217-274-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Naveen Manchanda is a Hematologist and a Hematologist Oncology provider in Indianapolis, Indiana. Dr. Manchanda and is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Sickle Cell Disease, Deep Vein Thrombosis, Atypical Hemolytic Uremic Syndrome (aHUS), D-Plus Hemolytic Uremic Syndrome, and Bone Marrow Aspiration. Dr. Manchanda is currently accepting new patients.

Expertise in
69
conditions
Dr. Chandler H. Park
Hematology Oncology | Hematology | Oncology
Expertise in
69
conditions
Dr. Chandler H. Park
Hematology Oncology | Hematology | Oncology

Norton Hospitals Inc

245 Atwood St, 
Corydon, IN 
 (53.4 mi)
812-734-0912
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chandler Park is a Hematologist Oncology specialist and a Hematologist in Corydon, Indiana. Dr. Park and is rated as a Distinguished provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Chromophobe Renal Cell Carcinoma, Familial Wilms Tumor 2, WT1-Related Wilms Tumor Syndromes, and Choriocarcinoma. Dr. Park is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile